PMID- 27988512
OWN - NLM
STAT- MEDLINE
DCOM- 20170315
LR  - 20220316
IS  - 1423-0143 (Electronic)
IS  - 1420-4096 (Linking)
VI  - 41
IP  - 6
DP  - 2016
TI  - Urine Epidermal Growth Factor, Monocyte Chemoattractant Protein-1 or Their Ratio 
      as Biomarkers for Interstitial Fibrosis and Tubular Atrophy in Primary 
      Glomerulonephritis.
PG  - 997-1007
LID - 10.1159/000452595 [doi]
AB  - BACKGROUND/AIMS: The degree of tubular atrophy and interstitial fibrosis (IFTA) 
      is an important prognostic factor in glomerulonephritis. Imbalance between 
      pro-inflammatory cytokines such as monocyte chemoattractant protein- 1 (MCP-1) 
      and protective cytokines such as epidermal growth factor (EGF) likely determine 
      IFTA severity. In separate studies, elevated MCP-1 and decreased EGF have been 
      shown to be associated with IFTA severity. In this study, we aim to evaluate the 
      predictive value of urinary EGF/MCP-1 ratio compared to each biomarker 
      individually for moderate to severe IFTA in primary glomerulonephritis (GN). 
      METHODS: Urine samples were collected at biopsy from primary GN (IgA nephropathy, 
      focal and segmental glomerulosclerosis, minimal change disease, membranous 
      nephropathy). MCP-1 and EGF were analyzed by enzyme-linked immunosorbent assay. 
      RESULTS: EGF, MCP-1 and EGF/MCP-1 ratio from primary GN, all correlated with IFTA 
      (n=58). By univariate analysis, glomerular filtration rate, EGF, and EGF/MCP-1 
      ratio were associated with IFTA. By multivariate analysis, only EGF/MCP-1 ratio 
      was independently associated with IFTA. EGF/MCP-1 ratio had a sensitivity of 88% 
      and specificity of 74 % for IFTA. EGF/MCP-1 had good discrimination for IFTA 
      (AUC=0.85), but the improvement over EGF alone was not significant. CONCLUSION: 
      EGF/MCP-1 ratio is independently associated IFTA severity in primary 
      glomerulonephritis, but the ability of EGF/MCP-1 ratio to discriminate moderate 
      to severe IFTA may not be much better than EGF alone.
CI  - (c) 2016 The Author(s) Published by S. Karger AG, Basel.
FAU - Worawichawong, Supanat
AU  - Worawichawong S
AD  - Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol 
      University, Bangkok, Thailand.
FAU - Worawichawong, Suchin
AU  - Worawichawong S
FAU - Radinahamed, Piyanuch
AU  - Radinahamed P
FAU - Muntham, Dittapol
AU  - Muntham D
FAU - Sathirapongsasuti, Nuankanya
AU  - Sathirapongsasuti N
FAU - Nongnuch, Arkom
AU  - Nongnuch A
FAU - Assanatham, Montira
AU  - Assanatham M
FAU - Kitiyakara, Chagriya
AU  - Kitiyakara C
LA  - eng
PT  - Journal Article
DEP - 20161219
PL  - Switzerland
TA  - Kidney Blood Press Res
JT  - Kidney & blood pressure research
JID - 9610505
RN  - 0 (Biomarkers)
RN  - 0 (Chemokine CCL2)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Adult
MH  - Atrophy/diagnosis/pathology/urine
MH  - Biomarkers/urine
MH  - Chemokine CCL2/*urine
MH  - Epidermal Growth Factor/*urine
MH  - Female
MH  - Fibrosis/*diagnosis/urine
MH  - Glomerulonephritis/*pathology
MH  - Humans
MH  - Kidney Tubules/*pathology
MH  - Male
MH  - Middle Aged
MH  - Sensitivity and Specificity
MH  - Severity of Illness Index
EDAT- 2016/12/19 06:00
MHDA- 2017/03/16 06:00
CRDT- 2016/12/19 06:00
PHST- 2016/10/21 00:00 [accepted]
PHST- 2016/12/19 06:00 [pubmed]
PHST- 2017/03/16 06:00 [medline]
PHST- 2016/12/19 06:00 [entrez]
AID - 000452595 [pii]
AID - 10.1159/000452595 [doi]
PST - ppublish
SO  - Kidney Blood Press Res. 2016;41(6):997-1007. doi: 10.1159/000452595. Epub 2016 
      Dec 19.